Arcus biosciences reports third-quarter 2024 financial results and provides a pipeline update

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended september 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting tigit, hif-2a, cd73, the a2a/a2b receptors, cd-39, axl and pd-1 — across multiple common cancers. “through.
RCUS Ratings Summary
RCUS Quant Ranking